| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of University Medicine, Southampton General Hospital and 2 St. Mary's Hospital, Portsmouth, UK
CORRESPONDENCE: S. Evans, St. Mary's Hospital, Milton road, Portsmouth, PO3 6AD, UK. Fax: 44 2392866735. E-mail: simon.evans@porthosp.nhs.uk
Keywords: community-acquired pneumonia, cytokines, disease severity score
Received: December 12, 2001
Accepted May 14, 2002
Pro-inflammatory and anti-inflammatory cytokines are important mediators in the host response to infection. In contrast to the pro-inflammatory cytokines little is known about anti-inflammatory cytokines in community-acquired pneumonia (CAP) and their relation to disease severity.
Circulating levels of three pro-inflammatory cytokines (interleukin (IL)-1ß, IL-6 and tumour necrosis factor (TNF)-
IL-6, TNF-
Concentrations of anti-inflammatory cytokines were elevated on admission in community-acquired pneumonia but they did not correlate with disease severity scores.
) and two anti-inflammatory cytokines (IL-10, IL-1 receptor antagonist (IL-1ra)) were measured using an enzyme immunoassay on admission, day 3 and day 5 in 24 patients with CAP. The modified British Thoracic Society (BTS) prognostic rule and Acute Physiology and Chronic Health Evaluation (APACHE) II score were used to assess disease severity. , IL-10 and IL-1ra concentrations were detected in most patients on admission and decreased significantly on day 3 and day 5 in all survivors. A significant difference between the BTS high-risk and low-risk groups was only found for IL-6 (median (range) 477 pg·mL–1 (7.6–1402 pg·mL–1) versus 81.6 pg·mL–1 (0–943 pg·mL–1); p<0.05). IL-6 also correlated with the APACHE II scores on admission.
This article has been cited by other articles:
|
|
 |
|
  L. A. Diaz, E. M. Mortensen, A. Anzueto, and M. I. Restrepo Review: Novel targets in the management of pneumonia Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 387 - 400. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Calbo, M. Alsina, M. Rodriguez-Carballeira, J. Lite, and J. Garau Systemic Expression of Cytokine Production in Patients with Severe Pneumococcal Pneumonia: Effects of Treatment with a {beta}-Lactam versus a Fluoroquinolone Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2395 - 2402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Menendez, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, and A Torres Markers of treatment failure in hospitalised community acquired pneumonia Thorax, May 1, 2008; 63(5): 447 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Sibila, C. Agusti, A. Torres, S. Baquero, S. Gando, J. R. Patron, J. G. Morato, D. H. Goffredo, N. Bassi, and C. M. Luna Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response Eur. Respir. J., December 1, 2007; 30(6): 1167 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yende, E. I. Tuomanen, R. Wunderink, A. Kanaya, A. B. Newman, T. Harris, N. de Rekeneire, S. B. Kritchevsky, and for the Health ABC Study Preinfection Systemic Inflammatory Markers and Risk of Hospitalization Due to Pneumonia Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Agusti, A Rano, M Rovira, X Filella, N Benito, A Moreno, and A Torres Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients Thorax, December 1, 2004; 59(12): 1081 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Metzger, S. Nusair, D. Planer, V. Barash, O. Pappo, J. Shilyansky, and T. Chajek-Shaul Inhibition of Hepatic Gluconeogenesis and Enhanced Glucose Uptake Contribute to the Development of Hypoglycemia in Mice Bearing Interleukin-1{beta}- Secreting Tumor Endocrinology, November 1, 2004; 145(11): 5150 - 5156. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
